11.30% -0.13

Trevena Inc (TRVN)

개요 뉴스 가격 이력 옵션 체인 Financials 토론 예측 주식 분할

Relative Volume:

Trevena Inc Stock (TRVN) Company Profile

Healthcare (1171)

Biotechnology (661)

최신 SEC 제출 서류

TRVN's Discussions on Twitter

TRVN을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
TRVN Trevena Inc	1.02	0	3.13M	-40.29M	-33.08M	-3.20
ONC Beone Medicines Ltd Adr	255.86	26.69B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	450.50	114.81B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.232	41.83M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	84.34	6.60B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	493.22	65.36B	14.09B	4.50B	2.96B	39.28

Trevena Inc Stock (TRVN) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2021-03-15	개시	Oppenheimer	Perform
2020-09-14	개시	Guggenheim	Buy
2020-08-28	개시	Cantor Fitzgerald	Overweight
2019-05-31	재개	H.C. Wainwright	Buy
2018-11-05	다운그레이드	H.C. Wainwright	Buy → Neutral
2018-10-12	다운그레이드	Needham	Buy → Hold
2018-10-10	다운그레이드	Jefferies	Buy → Hold
2017-11-08	재확인	Needham	Buy
2017-10-16	다운그레이드	Barclays	Overweight → Equal Weight
2017-10-12	재확인	H.C. Wainwright	Buy
2017-05-08	재확인	Needham	Buy
2017-02-23	재확인	H.C. Wainwright	Buy
2017-02-22	재확인	FBR & Co.	Outperform
2017-02-02	개시	Ladenburg Thalmann	Buy
2017-01-09	개시	H.C. Wainwright	Buy
2017-01-05	개시	Oppenheimer	Outperform
2016-05-17	재확인	FBR Capital	Outperform
2016-05-17	재확인	Needham	Buy
2016-03-29	개시	FBR Capital	Outperform
2015-09-01	재확인	Wedbush	Outperform
2015-08-03	개시	Brean Capital	Buy

Trevena Inc 주식(TRVN)의 최신 뉴스

Trevena Inc (TRVN) 재무 분석

Trevena Inc (TRVN)

Trevena Inc Stock (TRVN) Company Profile

TRVN을(를) 다른 주식과 비교

Trevena Inc Stock (TRVN) Upgrades & Downgrades

Trevena Inc 주식(TRVN)의 최신 뉴스

TREVENA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Trevena, Inc. To Contact The Firm - ACCESS Newswire

Acute Pain Drug Pipeline Analysis: Market Overview, Trends, and Future Growth (2034) - openPR.com

Trevena to Present at the H.C. Wainwright Global Investment Conference - The Globe and Mail

Opioid Drugs Market in 2025-2032 Detailed Study Analysis with - openPR.com

Financial Comparison: Adicet Bio (NASDAQ:ACET) & Trevena (NASDAQ:TRVN) - Defense World

Trevena (TRVN) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws; Investors Who Suffered Losses Exceeding $50,000 Encouraged to Contact the Firm - ACCESS Newswire

COVID-19 Therapeutics Market Current Scenario with Future Aspect Analysis - openPR.com

Opioid Drugs Market: Investment Analysis & Growth Opportunity - openPR.com

Highest-Paid CEOs2024 - AFL-CIO

Trevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.com - Defense World

Biopharma Dealmaking Quarterly Statistics, Q2 2013 - insights.citeline.com

Block & Leviton Files Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire

Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com - Defense World

Aviation Co. Says Workers' Class Action Too Broad - Law360

Block & Leviton Reminds Shareholders of Securities Class Action Against Trevena, Inc. (TRVN); Investors Who Suffered Losses Exceeding $50,000 Are Encouraged to Contact The Firm - ACCESS Newswire

Press Release Distribution & PR Platform - ACCESS Newswire

StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN) - Defense World

Trevena (NASDAQ:TRVN) Stock Crosses Below 200 Day Moving Average – Time to Sell? - Defense World

Opioid Drugs Market Detailed In New Research Report 2025-2032 | - openPR.com

Trevena Delays Yearly Report Filing - TipRanks

Trevena (TRVN) Expected to Announce Quarterly Earnings on Monday - Defense World

Delisting of Securities of Patria Latin American Opportunity Acquisition Corp.; Trevena, Inc.; Seelos Therapeutics, Inc.; DP Cap Acquisition Corp I; Chain Bridge I; Qomolangma Acquisition Corp.; Gaucho Group Holdings, Inc.; Mountain Crest Acquisition Corp. V - The Manila Times

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatm - The Manila Times

Global Post Operative Pain Management Market Advancements Highlighted by Forecast: Key Growth Drivers, Tren... - WhaTech

Ten option delistings on March 24th - TipRanks

Trevena (NASDAQ:TRVN) Stock Price Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World

StockNews.com Begins Coverage on Trevena (NASDAQ:TRVN) - The AM Reporter

Opioid Drugs Market to Witness Remarkable Growth with Johnson & Johnson, Endo International plc - openPR

Trevena (NASDAQ:TRVN) Now Covered by Analysts at StockNews.com - Defense World

Trevena, Inc. to Host Earnings Call - ACCESS Newswire

Trevena (NASDAQ:TRVN) Now Covered by StockNews.com - Defense World

Opioid Drugs Market Growth, Demand Trends, Size & Competitive - openPR

Trevena (NASDAQ:TRVN) Research Coverage Started at StockNews.com - Defense World

Promising Automotive Stocks To Keep An Eye On – February 04th - ETF Daily News

Trevena Announces Board and Executive ChangesOn January 31, 2025, Trevena, Inc. (NASDAQ:TRVN) filed a Form 8-K with the Securities and Exchange Commission, detailing significant departures and appointments within the company.In line with ongoin - Defense World

Trevena Implements Cost-Cutting Measures Amid Leadership Changes - TipRanks

Trevena (NASDAQ:TRVN) Shares Cross Below 200 Day Moving Average – Time to Sell? - Defense World

Trevena discontinues OLINVYK injection sales By Investing.com - Investing.com Canada

Trevena discontinues OLINVYK injection sales - Investing.com

Trevena (NASDAQ:TRVN) Stock Price Crosses Above Fifty Day Moving Average – What’s Next? - Defense World

Trevena (NASDAQ:TRVN) Coverage Initiated at StockNews.com - Defense World

Trevena Inc (TRVN) 재무 분석

매출

순이익

현금흐름

주당 순 이익

TRVN과 유사한 종목